Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13346MR)

This product GTTS-WQ13346MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13346MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5382MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ5011MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ8906MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ15103MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ11093MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ11641MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ5638MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ5692MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW